Drugs / Oshadi R
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01201018 | Jan 2011 → May 2012 | cancer, metastatic neoplasm | Oshadi Drug Administration | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01627795 | Dec 2016 → Aug 2018 | mesothelioma | Oshadi Drug Administration | Suspended | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02462265 | Jan 2017 → Jun 2018 | acute myeloid leukemia, lymphoid leukemia | Oshadi Drug Administration | Suspended | No outcome recorded |
| Phase 2 | NCT02134990 | Jun 2014 → Jan 2019 | non-small cell lung carcinoma | Oshadi Drug Administration | Unknown | No outcome recorded |
| Phase 2 | NCT02007317 | Nov 2013 → Mar 2017 | basal cell carcinoma, susceptibility to, 7 | Oshadi Drug Administration | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oshadi R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02134990 ↗ |
| Modality | Protein / enzyme biologic | “Oshadi R (RNase in Oshadi carrier)” NCT02462265 ↗ |
| Route | Oral | “that will be administered orally” NCT01201018 ↗ |